DWM
GLUE icon

Dogwood Wealth Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Dogwood Wealth Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Hold
54
– – ﹤0.01% 737
2026
Q1 		$888 Buy
+54
New +$1.03K ﹤0.01% 767

Other funds holding GLUE

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MFA
Mayflower Financial Advisors Boston, Massachusetts $1.16B AUM 24.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Dogwood Wealth Management's GLUE Position: Q2 2026 in Review

Dogwood Wealth Management held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 54 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Dogwood Wealth Management first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Dogwood Wealth Management held 54 shares of Monte Rosa Therapeutics worth $1.31K as of Q2 2026.
  • Dogwood Wealth Management left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Dogwood Wealth Management's portfolio in Q2 2026, its #737 holding.
  • Dogwood Wealth Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 8 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.